From CNBC: 2024-12-04 06:46:03

Eli Lilly’s Zepbound weight loss drug outperformed Novo Nordisk’s Wegovy in a head-to-head clinical trial, showing 20.2% weight loss versus 13.7% after 72 weeks. Zepbound also had a 47% higher relative weight reduction and better results in other studies. Analysts predict Zepbound could become the best-selling drug of all time.

The trial included 751 obese or overweight patients with at least one weight-related medical condition. Common gastrointestinal side effects were mild to moderate. Zepbound and Wegovy cost around $1,000 per month without insurance coverage, despite high demand. Both drugs target gut hormones but differ in their mechanisms.

Eli Lilly plans to publish the trial results in a peer-reviewed journal and present them at a medical meeting next year. The weight loss drug market is expected to reach $150 billion yearly by the early 2030s. Zepbound’s approval in late 2023 has led to increased manufacturing capacity to meet demand, with all doses now listed as “available” by the FDA.



Read more at CNBC: Eli Lilly Zepbound causes more weight loss than Novo Nordisk Wegovy: Trial